Correction: High seroprevalence of antibodies against SARS-CoV-2 among healthcare workers 8 months after the first wave in Aden, Yemen
Rami Malaeb, Nagwan Yousef, Omar Al-Nagdah, Qassem Hussein Ali, Mohammed Ali Saleh Saeed, Amna Haider, Evgenia Zelikova, Nada Malou, Sonia Guiramand, Clair Mills, Francisco Luquero, Klaudia Porten

Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsSARS-CoV-2 and COVID-19 Research · vaccines and immunoinformatics approaches · COVID-19 Clinical Research Studies
There are errors in the Funding and Competing Interests statements. The correct statements are:
Funding: The study was funded by Médecins Sans Frontières (MSF) France. MSF provided support in the form of salaries for NY, OAN, QHA, MASS, EZ, NM, SG, and CM. The specific roles of these authors are articulated in the ‘author contributions’ section. Additionally, two-thirds of Epicentre’s budget is funded by MSF, therefore, MSF indirectly supports Epicentre staff. MSF also provided comprehensive support for this study, including funding for human resources and materials. Specifically, MSF covered the costs of rapid diagnostic tests and supported the Aden National Blood Transfusion and Research Centre’s laboratory work required for our analysis. Coauthors affiliated with MSF contributed to the study design, data collection, and analysis, but the funder otherwise had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have read the journal’s policy and have the following competing interests to declare: MSF provided support in the form of salaries for NY, OAN, QHA, MASS, EZ, NM, SG, and CM. This does not alter our adherence to PLOS Global Public Health policies on sharing data and materials. There are no patents, products in development, or marketed products associated with this research to declare.
The reference list from the paper itself. Each links out to its DOI / PubMed record.
- 1Malaeb R, Yousef N, Al-Nagdah O, Ali QH, Saeed MAS, Haider A, et al. (2022) High seroprevalence of antibodies against SARS-Co V-2 among healthcare workers 8 months after the first wave in Aden, Yemen. PLOS Glob Public Health 2(11): e 0000767. 10.1371/journal.pgph.000076736962647 PMC 10022234 · doi ↗ · pubmed ↗
